

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization
International Bureau**



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/86304 A2

(51) International Patent Classification: G01N 33/68

51373 Leverkusen (DE). HENNIG, Guido [DE/DE];

(21) International Application Number: PCT/EP01/04696

Elmar-Reinhold [DE/DE]; Dorfstr. 28, 58239 Schwerin
DE-AUTHEUR: Michael A. GIMMEL

(22) International Filing Date: 26 April 2001 (26.04.2001)

BURT, Alastair, D. [GB/GB]: The Gables, Fairmoor

(25) Filing Language: English

Massimo [IT/IT]; Via Stefano Ussi 54, I-50018 Scandicci

(26) Publication Language: English

Bubenreuth (DE).

(30) Priority Data:

Common Representative: **BAUER AKTIENGESELLSCHAFT**, 51368 Leverkusen (DE)

(71) **Applicants (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE). BAYER CORPORATION [US/US]; 100 Bayer Road, Pittsburgh, PA 15205 (US).**

• **Designated States (regional):** European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(72) Inventors; and

Published:

(75) **Inventors/Applicants (for US only):** **VÖLKER, Michael** [D/E/D]; Morgengraben 2, 51061 Köln (D). **BECKA, Michael** [D/E/D]; Erlenweg 5, 59469 Ense (D). **KROLL, Werner** [D/E/D]; Pfaffenberger Weg 310, 42659 Solingen (D). **KNORR, Andreas** [D/E/D]; Trillser Graben 10, 40699 Erkrath (D). **UNGER, Sylvia** [D/E/D]; Fischergasse 2, 69117 Heidelberg (D). **GEHRMANN, Mathias** [D/E/D]; Alte Landstr. 140,

without international search report and to be republished upon receipt of that report entirely in electronic form (except for this front page) and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

01/86304 A2

(54) Title: ASSESSMENT OF LIVER FIBROSIS SCORING WITH SERUM MARKER ALGORITHMS

Assessment of Liver Fibrosis Scoring with Serum Marker Algorithms

Progressive fibrotic diseases of the liver are a major cause of morbidity and mortality throughout the world. Recent scientific advances demonstrate that the pathogenic process of fibrosis in liver is critically dependent on proliferation and activation of hepatic stellate cells (also called lipocytes, fat-storing or Ito cells) which synthesize and secrete excess extracellular matrix proteins (1). Moreover it is evident that this process is common to liver disease of all aetiologies. Of particular importance are chronic viral hepatitis B and C and alcoholic liver disease as well as autoimmune and genetic liver diseases, all of which lead to clinical problems via the common final pathway of progressive liver fibrosis, with the eventual development of cirrhosis.

An important concept is the distinction between hepatic fibrosis and cirrhosis. Hepatic fibrosis is a reversible accumulation of extracellular matrix in response to chronic injury in which nodules have not yet developed, whereas cirrhosis implies an irreversible process, in which thick bands of matrix fully encircle the parenchyma, forming nodules. Consequently, any therapy must be directed towards patients with reversible disease (fibrosis), which will require early identification and monitoring of those at risk (2).

Severity and progression of liver fibrosis are difficult to assess, with liver biopsy currently remaining the most reliable clinical method. The qualitative evaluation of hepatic fibrosis by biopsies is limited by interobserver variability. Biopsies are clearly inadequate for the early clinical phase of drug development, where there is an imperative to employ less invasive methods that identify effective compounds within a commercially acceptable time frame, usually measured in weeks to a maximum of three months of experimental therapeutic exposure. Further disadvantages are the low diagnostic specificity and the risk of bleeding. Therefore there is a need for surrogate markers of liver fibrosis. Serum tests allow a non-invasive assessment of fibrogenesis and fibrolysis in the liver and can be done repeatedly and at short time intervals (3).

(fibrogenesis) and extracellular matrix degradation (fibrolysis) reflect the amount of extracellular matrix present, the degree of fibrosis or the ongoing process of architectural change of the liver (4).

5 The current state of the art in measuring surrogate markers of liver fibrosis is poorly developed. Previous studies have suggested that serum levels of extracellular matrix proteins (or their cleavage fragments) may be used to assess the severity and progression of liver fibrosis (4,5, US 5 316 914, EP 0 283 779). Different serum markers have been investigated and correlations with liver biopsies and and severity of liver 10 diseases have been found (6).

Some of the makers used for the assessment of liver fibrosis are PIINP, Laminin, Hyaluronan, Collagen IV, TIMP-1, Tenascin, MMP-2 and Fibronectin. Markers are measured and their capability to assess liver fibrosis has been shown. Nevertheless, 15 the diagnostic values of each single marker is not accurate and specific to assess fibrosis scores.

Therefore combinations of markers are discussed to increase the diagnostic value the simple biological index PGA combining prothrombin time (PT), serum gamma-glutamyl transpeptidase (GGT) and apolipoprotein A1 (Apo A1) and the index PGAA which includes alpha-2-macroglobulin (A₂M) to the PGA index have been described for the diagnosis of alcoholic liver disease in drinkers (7,8). Although the PGA and PGAA index have been combined with single serum markers (9, 10) serum 20 markers have not been used for establishing algorithms for the assessment of liver 25 diseases.

In this invention serum markers of the extracellular matrix are assembled together in a panel leading to a set of markers whose measurement will enable the calculation of an algorithm and the use of such a derived algorithm for the prediction of liver fibrosis histological score. For this purpose discriminant function analysis is used to de- 30

rithms are derived from the set of markers N-terminal procollagen III propeptide (PIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex.

5 Generally, all new techniques have to be validated against existing standard techniques, provided there are any. The current "gold-standard" to assess fibrosis in the liver is the liver biopsy. With the biopsy, some randomly taken tissue out of the liver is cut into slices which become examined by an expert using a microscope. There are a lot of problems associated with liver biopsies inducing some uncertainty: distribution of fibrosis in the liver (clustered fibrosis and the needle might have hit regions of the liver not affected by fibrosis), failed sample preparation (e.g. not enough tissue material), and pathologist's individuality and preferences (individual assessments).
10 Furthermore, the fibrotic state of the liver is usually described using scores and there are a lot of different, possibly incompatible scoring systems (e.g. Scheuer Score, Ishak Scores, etc.).
15

For example, in a study with 24 patients, two independent pathologists had to score the same biopsy samples for each patient at two different time-points using two different scoring systems. The number of assessments where the two pathologists came to identical results ranged from only 36% to 46%.

20 The new technique is based on measuring serum parameters, which are directly associated with the fibrotic process, and combining them on a mathematical level yielding a fixed assessment procedure.
25 In order to validate the new technique the "gold-standard" is not the best but the only mean, since a priori both methods do not investigate comparable endpoints: whereas the serum parameters characterize dynamic processes, the biopsy characterizes the fibrotic manifestation at a fixed time-point. There may be a highly active fibrotic process in the liver although fibrotic tissue has not yet been developed. In contrast, there may be large clusters of fibrotic tissue in the liver but the fibrotic activity

Although, some mathematical functions of serum parameters yielded statistically significant different mean values in different biopsy score stages. Discriminant analyses using the "gold-standard" were chosen in order to investigate the diagnostic power of those mathematical functions of serum parameters.

Determination of concentrations of serum markers and subsequent calculation of an algorithm can also be used to make decisions whether or not a biopsy has to be taken and whether treatment should be started or continued or stopped. Therefore assignment of patients into a group of biopsy scores without taken a biopsy is advantageous. Categorization of patients into groups, e.g. mild versus serious fibrosis, by using algorithms is a benefit of the invention described.

Description of the immunoassays

15

The markers N-terminal procollagen III propeptide (PIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex are used for algorithms.

20

The markers are measured by making use of sandwich immunoassays. The immunoassays of the invention comprises reaction of two antibodies with human fluid samples, wherein the capture antibody specifically binds to one epitope of the marker. The second antibody of different epitope specificity is used to detect this complex. Preferably the antibodies are monoclonal antibodies and both antibodies of said two antibodies of the assay specifically bind to the protein.

25

Antibody or other similar term used herein includes a whole immunoglobulin either monoclonal or polyclonal as well as antigenic fragments or immunoreactive fragments which specifically bind to the marker, including Fab, Fab', F(ab')₂ and F(v).

30

Antibody includes also binding-proteins, especially Hyaluronic acid binding protein (HABP)

The human fluid samples used in the assays of the invention can be any samples that contain the markers, e.g. blood, serum, plasma, urine, sputum or broncho alveolar lavage (BAL). Typically a serum or plasma sample is employed.

5 Antibodies of the invention can be prepared by techniques generally known in the art, and are typically generated to a sample of the markers.

10 The second antibody is conjugated to a detector group, e.g. alkaline phosphatase, horseradish peroxidase, or a fluorescence dye. Conjugates are prepared by techniques generally known in the art.

Concentration of the markers in human fluids are measured and algorithms calculated to assess the degree of fibrosis.

15 **Statistical Background**

Discriminant function analysis is used to determine which variables discriminate between two or more naturally occurring groups. Computationally, it is very similar to analysis of variance. The basic idea underlying discriminant function analysis is to 20 determine whether groups differ with regard to the mean of a variable, and then to use that variable to predict group membership (e.g., of new cases). Stated in this manner, the discriminant function problem can be rephrased as a one-way analysis of variance (ANOVA) problem. Specifically, one can ask whether or not two or more groups are significantly different from each other with respect to the mean of a particular variable. If the means for a variable are significantly different in different 25 groups, then we can say that this variable discriminates between the groups. In the case of a single variable, the final significance test of whether or not a variable discriminates between groups is the *F* test. *F* is essentially computed as the ratio of the between-groups variance in the data over the pooled (average) within-group variance. 30 If the between-group variance is significantly larger then there must be significant

Usually, one includes several variables in a study in order to see which one(s) contribute to the discrimination between groups. In that case, we have a matrix of total variances and co-variances; likewise, we have a matrix of pooled within-group variances and co-variances. We can compare those two matrices via multivariate F tests in order to determine whether or not there are any significant differences (with regard to all variables) between groups. This procedure is identical to multivariate analysis of variance or MANOVA. As in MANOVA, one could first perform the multivariate test, and, if statistically significant, proceed to see which of the variables have significantly different means across the groups. Thus, even though the computations with multiple variables are more complex, the principal reasoning still applies, namely, that we are looking for variables that discriminate between groups, as evident in observed mean differences.

15 For a set of observations containing one or more quantitative variables and a classification variable defining groups of observations, the discrimination procedure develops a discriminant criterion to classify each observation into one of the groups. Post hoc predicting of what has happened in the past is not that difficult. It is not uncommon to obtain very good classification if one uses the same cases from which the discriminant criterion was computed. In order to get an idea of how well the current discriminant criterion "performs", one must classify (a priori) different cases, that is, cases that were not used to estimate the discriminant criterion. Only the classification of new cases allows us to assess the predictive validity of the discriminant criterion. In order to validate the derived criterion, the classification can be applied to other data sets. The data set used to derive the discriminant criterion is called the training or calibration data set.

20

25

30

The discriminant criterion (function(s) or algorithm), is determined by a measure of generalized squared distance. It can be based on the pooled co-variance matrix yielding a linear function. Either Mahalanobis or Euclidean distance can be used to

For the development of a discriminant algorithm, data of a group of subjects of an observational liver fibrosis of study were analyzed. Liver fibrosis scoring systems under view were

- 5 - the Scheuer Score (0-4),
- the Modified Ishak Score (HAI) A - Interface Hepatitis (0-4),
- the Modified Ishak Score (HAI) B - Confluent Necrosis (0-6),
- the Modified Ishak Score (HAI) C - Spotty Necrosis (0-4),
- the Modified Ishak Score (HAI) D - Portal Inflammation (0-4),
- 10 - the Modified HAI Score (Ishak Score) (0-6).

Applying a stepwise discriminant analysis, for example the following functions of serum parameters showed to have major impact on the corresponding scoring type.

<i>Scoring Type</i>	<i>Surrogate Parameters</i>
Scheurer Score: $\ln(\text{TIMP-1})$	$\ln(\text{Collagen VI}) / \ln(\text{Hyaluronan} / \text{Laminin})$
Modified Ishak Score A - Interface Hepatitis: $\ln(\text{TIMP-1})$	$\ln(\text{Collagen VI}) / \ln(\text{Hyaluronan})$
Modified Ishak Score B - Confluent Necrosis: $\ln(\text{Hyaluronan})$	$\ln(\text{Collagen VI}) / \ln(\text{Collagen VI} / \text{Tenascin})$
Modified Ishak Score C - Spotty Necrosis: $\ln(\text{Hyaluronan})$	$\ln(\text{MMP-9/TIMP-1}) / \ln(\text{MMP-9/TIMP-1} / \text{complex Tenascin})$
Modified Ishak Score D - Portal Inflammation: $\ln(\text{Laminin})$	$\ln(\text{Collagen VI}) / \ln(\text{Collagen VI} / \text{TIMP-1})$
Modified Ishak Score - Stage: $\ln(\text{TIMP-1})$	$\ln(\text{Collagen VI}) / \ln(\text{Hyaluronan} / \text{Laminin})$

A corresponding discriminant analysis yielded the linear discriminating functions which can be used for calculation and prediction of biopsy score. The algorithms can be applied to every known scoring system (e.g. Scheuer Score, Ishak Score, Netavir Score, Ludwig Score, HAI Score).

5

Algorithms can be used to predict the biopsy score of a patient (e.g. score 0, 1, 2, 3, ...) or to predict a group of scores (category) a patient belongs to (e.g. mild fibrosis; score 0 to 1).

10 Discriminating functions used includes combinations of markers from the list of N-terminal procollagen III propeptide (PIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex and also factors between -1000 and +1000.

15 Different scores need different algorithm form the list of markers and factors.

ExamplesExample 1

5 Algorithms for Scheuer Score

The following algorithms 1, 2 and 3 were calculated by correlating biopsies assessed by the Scheuer scoring system and serum marker concentrations of a group of patients with liver diseases:

.0

Algorithm 1:

```
[0] : -108.861+0.283*LOG(COL_VI/HYAL)-1.050*LOG(HYAL/LAM)+35.372*LOG(TIMP1)  
[1] : -114.231+0.195*LOG(COL_VI/HYAL)-0.654*LOG(HYAL/LAM)+36.158*LOG(TIMP1)  
[2] : -120.649-0.998*LOG(COL_VI/HYAL)-2.102*LOG(HYAL/LAM)+36.925*LOG(TIMP1)  
[3] : -123.672-1.281*LOG(COL_VI/HYAL)-1.344*LOG(HYAL/LAM)+37.163*LOG(TIMP1)  
[4] : -133.207-2.186*LOG(COL_VI/HYAL)-1.602*LOG(HYAL/LAM)+38.188*LOG(TIMP1)
```

Algorithm 2:

```
[0] : -75.18797+23.04542*LOG(TIMP1)-0.583641*LOG(COL_VI/HYAL)-0.140956*LOG(HYAL/LAM)  
[1] : -76.1526+23.15895*LOG(TIMP1)-0.963402*LOG(COL_VI/HYAL)-0.009472*LOG(HYAL/LAM)  
[2] : -78.62662+23.32161*LOG(TIMP1)-1.227332*LOG(COL_VI/HYAL)-0.067969*LOG(HYAL/LAM)  
[3] : -83.09285+23.64493*LOG(TIMP1)-2.181493*LOG(COL_VI/HYAL)-0.300241*LOG(HYAL/LAM)  
[4] : -93.89732+24.86246*LOG(TIMP1)-2.841299*LOG(COL_VI/HYAL)-0.136885*LOG(HYAL/LAM)
```

5

Algorithm 3:

```
[0] : -95.39661+17.66025*LOG(HYAL)-0.820836*LOG(COL_IV)+0.245778*LOG(COL_VI/PIIINP)-  
      17.79663*LOG(COL_VI/TIMP1)-14.96754*LOG(HYAL/MMP2)-0.279356*LOG(LAM/MMP9T)  
  
[1] : -95.84457-17.62365*LOG(HYAL)-0.667854*LOG(COL_IV)+0.155707*LOG(COL_VI/PIIINP)-  
      18.0407*LOG(COL_VI/TIMP1)-14.42688*LOG(HYAL/MMP2)-0.554323*LOG(LAM/MMP9T)  
  
[2] : -99.13575+17.76656*LOG(HYAL)-0.978731*LOG(COL_IV)-0.12995*LOG(COL_VI/PIIINP)-  
      18.69948*LOG(COL_VI/TIMP1)-14.49353*LOG(HYAL/MMP2)-0.647247*LOG(LAM/MMP9T)  
  
[3] : -104.4554+18.38886*LOG(HYAL)-0.202832*LOG(COL_IV)-0.157058*LOG(COL_VI/PIIINP)-  
      18.70409*LOG(COL_VI/TIMP1)-14.49716*LOG(HYAL/MMP2)-0.340197*LOG(LAM/MMP9T)  
  
[4] : -119.8887+20.14719*LOG(HYAL)+0.959792*LOG(COL_IV)-0.80876*LOG(COL_VI/PIIINP)-  
      18.69873*LOG(COL_VI/TIMP1)-15.57103*LOG(HYAL/MMP2)-0.229757*LOG(LAM/MMP9T)
```

5 The algorithms were used to predict biopsy scores of a separate group of patients. The calculated scores were compared with scores determined by a single pathologist (case B), with a consensus score of 3 pathologists (case C) and with the range covered by all pathologists (case A). Kappa values, negative predictive values (NPV) for score 0-1, positive predictive values (PPV) for score 2-4, sensitivities and specificities have also been calculated.

	Algorithm 1			Algorithm 2			Algorithm 3		
	C	A	B	C	A	B	C	A	B
Hit-Rate (%) [0]	33.3	38.9	35.0	17.1	40.0	13.7	20.0	41.4	16.8
Hit-Rate (%) [1]	36.8	42.7	36.0	80.7	81.6	75.8	74.6	77.2	71.7
Hit-Rate (%) [2]	25.8	42.4	19.0	0.0	36.8	0.0	0.0	34.2	5.1
Hit-Rate (%) [3]	26.1	34.8	22.2	6.4	17.0	5.2	12.8	21.3	9.3
Hit-Rate (%) [4]	63.0	63.0	55.9	62.5	52.5	43.8	43.8	47.1	
Hit-Rate (%) All	35.9	42.9	33.8	42.2	54.2	36.7	39.5	51.2	36.7
N	468	468	793	301	301	626	301	301	626
Kappa	0.175	0.268	0.151	.	0.199	.	0.124	0.310	0.121
L_Kappa	0.119	0.211	0.109	.	0.134	.	0.056	0.235	0.077
U_Kappa	0.231	0.325	0.192	.	0.265	.	0.191	0.385	0.165
P(Kappa=0)	<0.0001	<0.0001	<0.0001	.	<0.0001	.	<0.0001	<0.0001	<0.0001
NPV (%) [0-1]	61.6	63.8	62.8	91.8	92.4	85.5	88.0	89.1	81.6
PPV (%) [2-4]	66.1	75.1	66.3	31.6	46.2	35.4	35.0	48.7	39.0
Hit-Rate (%) All	63.5	68.4	64.2	68.4	74.4	65.8	67.4	73.4	64.9
Kappa	0.268	0.372	0.280	0.261	0.417	0.226	0.252	0.404	0.219
L_Kappa	0.182	0.291	0.214	0.160	0.315	0.152	0.146	0.299	0.142
U_Kappa	0.354	0.454	0.346	0.363	0.520	0.300	0.358	0.508	0.295
P(Kappa=0)	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001
Sensitivity	0.539	0.584	0.540	0.712	0.794	0.613	0.651	0.740	0.578
Specificity	0.729	0.791	0.739	0.679	0.730	0.671	0.681	0.732	0.674

Example 2

Algorithms for Ishak Score

5 The following algorithms 1, 2 and 3 were calculated by correlating biopsies assessed by the Ishak scoring system and serum marker concentrations of a group of patients with liver diseases:

Algorithm 1:

[0] : -107.752-0.347*LOG(COL_VI/HYAL)-1.493*LOG(HYAL/LAM)+34.879*LOG(TIMP1)
[1] : -112.550-0.301*LOG(COL_VI/HYAL)-1.086*LOG(HYAL/LAM)+35.617*LOG(TIMP1)
[2] : -114.626-0.760*LOG(COL_VI/HYAL)-1.270*LOG(HYAL/LAM)+35.819*LOG(TIMP1)
[3] : -121.339-2.065*LOG(COL_VI/HYAL)-2.910*LOG(HYAL/LAM)+36.593*LOG(TIMP1)
[4] : -119.289-1.009*LOG(COL_VI/HYAL)-1.271*LOG(HYAL/LAM)+36.449*LOG(TIMP1)
[5] : -125.551-2.966*LOG(COL_VI/HYAL)-2.536*LOG(HYAL/LAM)+36.797*LOG(TIMP1)
[6] : -133.055-3.256*LOG(COL_VI/HYAL)-2.329*LOG(HYAL/LAM)+37.695*LOG(TIMP1)

10

Algorithm 2:

[0] : -75.94035+23.20826*LOG(TIMP1)-0.911827*LOG(COL_VI/HYAL)-0.295297*LOG(HYAL/LAM)
[1] : -76.0885+23.14058*LOG(TIMP1)-1.221511*LOG(COL_VI/HYAL)-0.155608*LOG(HYAL/LAM)
[2] : -80.17664+23.6506*LOG(TIMP1)-1.41651*LOG(COL_VI/HYAL)-0.210415*LOG(HYAL/LAM)
[3] : -79.12945+23.42277*LOG(TIMP1)-1.582733*LOG(COL_VI/HYAL)-0.175959*LOG(HYAL/LAM)
[4] : -83.24617+23.7777*LOG(TIMP1)-2.174834*LOG(COL_VI/HYAL)-0.311583*LOG(HYAL/LAM)
[5] : -89.60186+24.2615*LOG(TIMP1)-3.237993*LOG(COL_VI/HYAL)-0.914309*LOG(HYAL/LAM)
[6] : -95.5774+25.11333*LOG(TIMP1)-3.293235*LOG(COL_VI/HYAL)-0.347014*LOG(HYAL/LAM)

Algorithm 3:

[0] : $-100.6452 + 17.18813 \cdot \text{LOG(HYAL)} + 15.20461 \cdot \text{LOG(COL_IV/HYAL)} + 0.515498 \cdot \text{LOG(COL_VI/PIIINP)}$
 $+ 3.309452 \cdot \text{LOG(LAM)} - 15.47806 \cdot \text{LOG(COL_IV/MMP2)} - 17.50773 \cdot \text{LOG(COL_VI/TIMP1)}$

[1] : $-98.87092 + 17.18161 \cdot \text{LOG(HYAL)} + 14.7876 \cdot \text{LOG(COL_IV/HYAL)} + 0.530071 \cdot \text{LOG(COL_VI/PIIINP)}$
 $+ 3.067209 \cdot \text{LOG(LAM)} - 14.74001 \cdot \text{LOG(COL_IV/MMP2)} - 17.62455 \cdot \text{LOG(COL_VI/TIMP1)}$

[2] : $-104.8869 + 17.78543 \cdot \text{LOG(HYAL)} + 15.25944 \cdot \text{LOG(COL_IV/HYAL)} + 0.352181 \cdot \text{LOG(COL_VI/PIIINP)}$
 $+ 3.175207 \cdot \text{LOG(LAM)} - 15.56044 \cdot \text{LOG(COL_IV/MMP2)} - 17.97986 \cdot \text{LOG(COL_VI/TIMP1)}$

[3] : $-102.8131 + 17.32281 \cdot \text{LOG(HYAL)} + 14.69307 \cdot \text{LOG(COL_IV/HYAL)} + 0.176959 \cdot \text{LOG(COL_VI/PIIINP)}$
 $+ 2.822227 \cdot \text{LOG(LAM)} - 15.15272 \cdot \text{LOG(COL_IV/MMP2)} - 18.37351 \cdot \text{LOG(COL_VI/TIMP1)}$

[4] : $-109.2574 + 18.44309 \cdot \text{LOG(HYAL)} + 15.53464 \cdot \text{LOG(COL_IV/HYAL)} - 0.152374 \cdot \text{LOG(COL_VI/PIIINP)}$
 $+ 2.957847 \cdot \text{LOG(LAM)} - 15.02773 \cdot \text{LOG(COL_IV/MMP2)} - 18.59138 \cdot \text{LOG(COL_VI/TIMP1)}$

[5] : $-116.8556 + 19.00778 \cdot \text{LOG(HYAL)} + 15.47539 \cdot \text{LOG(COL_IV/HYAL)} + 0.436656 \cdot \text{LOG(COL_VI/PIIINP)}$
 $+ 3.995456 \cdot \text{LOG(LAM)} - 15.54302 \cdot \text{LOG(COL_IV/MMP2)} - 18.53013 \cdot \text{LOG(COL_VI/TIMP1)}$

[6] : $-127.2084 + 21.66093 \cdot \text{LOG(HYAL)} + 17.77795 \cdot \text{LOG(COL_IV/HYAL)} - 0.631902 \cdot \text{LOG(COL_VI/PIIINP)}$
 $+ 3.589129 \cdot \text{LOG(LAM)} - 16.1393 \cdot \text{LOG(COL_IV/MMP2)} - 18.40445 \cdot \text{LOG(COL_VI/TIMP1)}$

The algorithms were used to predict biopsy scores of a separate group of patients.
5 The calculated scores were compared with scores determined by a single pathologist (case B), with a consensus score of 3 pathologists (case C) and with the range covered by all pathologists (case A). Kappa values, negative predictive values (NPV) for score 0-2, positive predictive values (PPV) for score 3-6, sensitivities and specificities have also been calculated.

	Algorithm 1			Algorithm 2			Algorithm 2		
	C	A	B	C	A	B	C	A	B
Hit-Rate (%) [0]	28.7	31.5	29.5	45.7	58.6	41.0	45.7	57.1	39.8
Hit-Rate (%) [1]	25.0	34.0	29.2	50.8	60.7	50.8	27.9	41.0	37.7
Hit-Rate (%) [2]	10.7	24.0	9.7	0.0	22.4	1.1	1.7	15.5	1.1
Hit-Rate (%) [3]	23.0	27.9	20.2	0.0	3.1	0.0	9.4	12.5	6.9
Hit-Rate (%) [4]	22.2	37.8	25.6	0.0	0.0	0.0	0.0	7.7	3.3
Hit-Rate (%) [5]	32.0	44.0	24.4	4.5	18.2	2.6	0.0	18.2	2.6
Hit-Rate (%) [6]	57.4	57.4	51.1	71.9	71.9	60.9	43.8	43.8	52.2
Hit-Rate (%) All	27.1	34.6	27.3	28.9	39.5	28.1	22.3	32.6	25.2
N	468	468	794	301	301	627	301	301	627
Kappa	0.138	0.228	0.136	0.031	0.093	0.041
L_Kappa	0.090	0.177	0.100	-0.02	0.039	0.006
U_Kappa	0.186	0.279	0.173	0.084	0.147	0.076
P(Kappa=0)	<0.0001	<0.0001	<0.0001	0.2293	0.0003	0.0152
NPV (%) [0-2]	57.2	59.4	59.1	89.9	91.0	83.9	77.8	80.4	75.1
PPV (%) [3-6]	71.9	79.5	74.2	40.2	50.9	41.5	47.3	55.4	48.1
Hit-Rate (%) All	63.0	67.3	65.0	71.4	76.1	67.6	66.4	71.1	64.8
Kappa	0.274	0.362	0.312	0.330	0.450	0.271	0.259	0.366	0.238
L_Kappa	0.191	0.283	0.249	0.223	0.346	0.195	0.147	0.257	0.160
U_Kappa	0.356	0.441	0.374	0.437	0.554	0.347	0.371	0.475	0.316
P(Kappa=0)	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001	<0.0001
Sensitivity	0.524	0.561	0.537	0.703	0.770	0.617	0.558	0.626	0.547
Specificity	0.757	0.816	0.781	0.717	0.758	0.697	0.714	0.752	0.699

Example 3

Receiver Operating Characteristic (ROC) Curves for Scheuer Score

5 Grouping the patients into categories no/mild fibrosis (score 0-1) and moderate/severe fibrosis (score 2-4) for the Scheuer score and calculating algorithms for the dichotomous outcome gave the following results:

Algorithm 4:

10 LOGIT =

7.11957755-0.67952658 LOG(TIMPI)+1.01832374*LOG(COL_VI/HYAL)+0.09461778*LOG(HYAL/LAM)

Algorithm 5:

LOGIT =

8.6908419-0.76944684*LOG(HYAL)-0.47836706*LOG(COL_IV)+0.43870798*LOG(COL_VI/PIINP)
+0.74453459*LOG(COL_VI/TIMP1)+0.05605262*LOG(HYAL/MMP2)-0.01871531*LOG(LAM/MMP9T)

5

The algorithms were used to calculate receiver operating characteristic curves for the categories no/mild fibrosis (score 0-1) and moderate/severe fibrosis (score 2-4) for the Scheuer score. The calculated scores were compared with scores determined by a single pathologist (case B), with a consensus score of 3 pathologists (case C) and 10 with the range covered by all pathologists (case A). Area under curve (AUC) values have been calculated.

		Algorithm 4			Algorithm 5		
		C	A	B	C	A	B
15	AUC	0.759	0.899	0.759	0.746	0.871	0.756
	N	295	295	569	291	291	562

Example 4

20 Receiver Operating Characteristic (ROC) Curves for Ishak Score

Grouping the patients into categories no/mild fibrosis (score 0-2) and moderate/severe fibrosis (score 3-6) for the Ishak score and calculating algorithms for the dichotomous outcome gave the following results:

25

Algorithm 4:

LOGIT =

7.22920269-0.68033581*LOG(TIMP1)+1.04300795*LOG(COL_VI/HYAL)+0.08483109*LOG(HYAL/LAM)

Algorithm 5:

LOGIT =

8.92321331-1.28340678*LOG(HYAL)-0.54350583*LOG(COL_IV/HYAL)+
0.47836792*LOG(COL_VI/PIINP)+0.02076678*LOG(LAM)+0.07719237*LOG(COL_IV/MMP2)
5 +
0.76194671*LOG(COL_VI/TIMP1)

The algorithms were used to calculate receiver operating characteristic curves for the categories no/mild fibrosis (score 0-2) and moderate/severe fibrosis (score 3-6) for
10 the Ishak score. The calculated scores were compared with scores determined by a single pathologist (case B), with a consensus score of 3 pathologists (case C) and with the range covered by all pathologists (case A). Area under curve (AUC) values have been calculated.

15	Algorithm 4			Algorithm 5		
	C	A	B	C	A	B
AUC	0.763	0.887	0.763	0.751	0.861	0.757
N	295	295	570	292	292	564

Literature

1. Friedman SL
The cellular basis of hepatic fibrosis: Mechanism and treatment strategies.
5 N Engl J Med 1993; 328: 1828-1835
2. Friedman SL
Molecular mechanism of hepatic fibrosis and principle of therapy
J Gastroenterol 1997; 32: 424-430
10
3. Hayasaka A, Saisho H
Serum markers as tools to monitor liver fibrosis
Digestion 1998; 59: 381-384
- 15 4. Schuppan D, Stolzel U, Oesterling C, Somasundaram R
Serum assays for liver fibrosis.
J Hepatol 1995; 22 (Suppl 2): 82-88
5. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H
20 Serum markers for connective tissue turnover in patients with chronic hepatitis C: A comparative analysis.
J Hepatol 1995; 23: 145-152
6. Wong VS, Hughes V, Trull A, Wight DGD, Petrik J, Alexander GJM
25 Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection
J Viral Hepatitis 1998; 5: 187-192
7. Poinard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chapu JC
30 A simple biological index for detection of alcoholic liver disease in drinkers

8. Naveau S, Poynard T, Benattat C, Bedossa P, Chaput JC
Alpha-2 macroglobulin and hepatic fibrosis:diagnostic interest
Dig Dis Sci 1994; 39: 2426-2432
9. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, Rifflet H, Maiga MY, Penneau-Fontbonne D, Cales P
Noninvasive diagnosis of hepatic fibrosis and cirrhosis
Gastroenterology 1997; 113: 1609-1616
10. Teare JP, Sherman D, Greenfield SM, Simpson J, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RPH
The Lancet 1993; 342: 895-898

Claims

1. A method for diagnosing liver fibrosis wherein two or more diagnostic markers are measured in a body fluid and the measurements are combined by mathematical algorithms.
5
2. A method according to claim 1 wherein the algorithms are characterized in a way that the diagnostic markers are selected from the group of N-terminal procollagen III propeptide (PIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex.
10
3. A method according to claim 1 wherein body fluid is blood, serum, plasma or urin.
4. A method according to claim 1 and 2 wherein the algorithms can be used to support, predict or substitute the histological score of a liver biopsy.
15
5. A method according claim 4 wherein the algorithms can be adjusted to match known scoring system (e.g. Scheuer score, Ishak score, HAI score, Ludwig score, Metavir score).
20
6. A method according to claim 1 and 2 wherein the algorithms can be used to categorize patients into groups of scores.
7. A method according to claim 4 and 6 wherein treatment decisions can be supported by the calculated score or the calculated score group.
25
8. A method according to claim 4 and 6 wherein clinical drug trials for liver diseases including dose-finding studies can be supported by the calculated score or the calculated score group.
30

9. A method according to claim 4 and 6 wherein decisions whether or not a biopsy should be taken can be supported by the calculated score or the calculated score group.
- 5 10. A method according claim 6 wherein patients can be classified as suffering from no/mild or moderate/severe liver fibrosis.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/86304 A3

(51) International Patent Classification⁷: **G01N 33/68.**
33/573

Wiedenhofstr. 46, 47798 Krefeld (DE). **BURCHARDT,**
Elmar-Reinhold [DE/DE]; Dorfstr. 28, 58239 Schwerte
(DE). **ARTHUR,** **Michael, J.** [GB/GB]; Slab Farm,
Slab Lane, West Wellow, Hampshire SO51 6BY (GB).
BURT, **Alastair, D.** [GB/GB]; The Gables, Fairmoor
Morphet, Northumberland NE 613 JL (GB). **PINZANI,**
Massimo [IT/IT]; Via Stefano Ussi 54, I-50018 Scandicci
(IT). **SCHUPPAN,** **Detlef** [DE/DE]; Baumzeit 2, 91088
Bubenreuth (DE).

(21) International Application Number: **PCT/EP01/04696**

(22) International Filing Date: 26 April 2001 (26.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(74) Common Representative: **BAYER AKTIENGESELLSCHAFT**: 51368 Leverkusen (DE).

(30) Priority Data:
00109063.8 28 April 2000 (28.04.2000) EP
2001A000813 13 April 2001 (13.04.2001) IT

(81) Designated States (national): AU, CA, JP, US.

(71) Applicants (for all designated States except US): **BAYER AKTIENGESELLSCHAFT** [DE/DE]; 51368 Leverkusen (DE). **BAYER CORPORATION** [US/US]; 100 Bayer Road, Pittsburgh, PA 15205 (US).

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(72) Inventors; and


Published:

(75) Inventors/Applicants (for US only): **VÖLKER, Michael** [DE/DE]; Morgengraben 2, 51061 Köln (DE). **BECKA, Michael** [DE/DE]; Erlenweg 5, 59469 Ense (DE). **KROLL, Werner** [DE/DE]; Pfaffenberger Weg 310, 42659 Solingen (DE). **KNORR, Andreas** [DE/DE]; Trillser Graben 10, 40699 Erkrath (DE). **UNGER, Sylvia** [DE/DE]; Fischergrasse 2, 69117 Heidelberg (DE). **GEHRMANN, Mathias** [DE/DE]; Alte Landstr. 140, 51373 Leverkusen (DE). **HENNIG, Guido** [DE/DE];

with international search report
entirely in electronic form (except for this front page) and
available upon request from the International Bureau

(88) Date of publication of the international search report:
4 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A3

(54) Title: DIAGNOSTIC OF LIVER FIBROSIS WITH SERUM MARKER ALGORITHMS

from the group N terminal propeptides for propeptide (MMPs) in patients with chronic liver diseases. The diagnostic accuracy of the algorithm is 84.4% for the detection of liver fibrosis. The algorithm can be used to predict the histological score of a liver biopsy.

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/EP 01/04696A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/68 G01N33/573

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	<p>C. PILETTE ET AL.: "Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores." JOURNAL OF HEPATOLOGY., vol. 28, no. 3, March 1998 (1998-03), pages 439-446, XP001019675 XX, XX the whole document</p> <p>----</p> <p>-/-</p>	1-10

 Further documents are listed in the continuation of box C Patent family members are listed in annex

- Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

K document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
9 October 2001	31/10/2001

INTERNATIONAL SEARCH REPORT

Interr [REDACTED] Application No
PCT/EP 01/04696

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No
Y	J. P. TEARE ET AL.: "Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis" LANCET THE., vol. 342, no. 8876, 9 October 1993 (1993-10-09), pages 895-898, XP002149457 LANCET LIMITED. LONDON., GB ISSN: 0140-6736 cited in the application the whole document ---	1-10
Y	EP 0 911 343 A (TOSOH CORPORATION ET AL.) 28 April 1999 (1999-04-28) abstract ---	1-10
Y	J. KROPP ET AL.: "Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases" CLINICAL CHEMISTRY, vol. 34, no. 10, October 1988 (1988-10), pages 2026-2030, XP002149458 WINSTON US the whole document ---	1-10
Y	J. GUÉCHOT ET AL.: "Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis." CLINICAL CHEMISTRY, vol. 42, no. 4, April 1996 (1996-04), pages 558-563, XP002149459 WINSTON US the whole document ---	1-10
Y	CHEMICAL ABSTRACTS, vol. 131, no. 24, 13 December 1999 (1999-12-13) Columbus, Ohio. US; abstract no. 321003, R. ENDO ET AL.: "Serial changes in the serum levels of type IV collagen, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in patients with acute and fulminant hepatitis" page 496; column 2; XP002149461 abstract & IWATE IGAKU ZASSHI, vol. 51, no. 4. 1999, pages 371-379. ---	1-10

INTERNATIONAL SEARCH REPORT

Interr [REDACTED] Application No
PCT/EP 01/04696

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No
Y	X. JI ET AL.: "Clinical significance of serum 7S collagen and type VI collagen levels for the diagnosis of hepatic fibrosis." CHINESE MEDICAL JOURNAL / ZHONGHUA YIXUE ZAZHI YINGWEN BAN., vol. 110, no. 3, 1997, pages 198-201, XP001019695 CHINESE MEDICAL ASSOCIATION, BEIJING., CN ISSN: 0366-6999 the whole document ---	1-10
Y	M. J. P. ARTHUR ET AL.: "Tissue inhibitors of metalloproteinases: role in liver fibrosis and alcoholic liver disease." ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH., vol. 23, no. 5, May 1999 (1999-05), pages 940-943, XP001019678 WILLIAMS AND WILKINGS, BALTIMORE, MD., US ISSN: 0145-6008 the whole document ---	1-10
Y	D. SCHUPPAN ET AL.: "Serummarker der Leberfibrose." DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, vol. 124, no. 41, 15 October 1999 (1999-10-15), pages 1213-1218, XP001019674 GEORG THIEME, STUTTGART, , DE ISSN: 0012-0472 the whole document ---	1-10
Y	A. E. KOSSAKOWSKA ET AL.: "Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis." AMERICAN JOURNAL OF PATHOLOGY., vol. 153, no. 6, December 1998 (1998-12), pages 1895-1902, XP001019668 PHILADELPHIA, PA., US ISSN: 0002-9440 the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 01/04696

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
EP 911343	A 28-04-1999	EP JP US	0911343 A2 11171898 A 6060255 A		28-04-1999 29-06-1999 09-05-2000